Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

The introduction of novel therapeutic agents for advanced prostate cancer has led to a wide
range of treatment options for patients with metastatic castration-resistant prostate cancer …

Despite many recent advances in the therapy for metastatic castration-resistant prostate
cancer (mCRPC), the disease remains incurable, although men suffering from this disease …

Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous
wide range of molecular tumor behavior and a high risk of progression. Early detection and …

Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease.
However, in recent years, several treatments have been shown to improve the outcome of …

Abstract Context Prostate cancer (PCa) is the most common noncutaneous malignancy and
the second leading cause of cancer mortality amongst men in the Western world. Up to 40 …

The exponential growth of novel therapies for the treatment of metastatic castration-resistant
prostate cancer (mCRPC) over the last decade has created an acute need for education and …

Context Until recently, the only approved agent for metastatic castration-resistant prostate
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …

Background Clinical trials have demonstrated the efficacy of several life-prolonging
therapies for metastatic castration-resistant prostate cancer (mCRPC); however, real-world …

Background The tumors of many patients with prostate cancer eventually become refractory
to androgen deprivation therapy with progression to metastatic castration-resistant disease …